SOURCES SOUGHT
A -- The Electronic Transmission of Molecular Genetics Data to State Cancer Registries
- Notice Date
- 2/26/2010
- Notice Type
- Sources Sought
- NAICS
- 622110
— General Medical and Surgical Hospitals
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- HHS-CDC-SS-2010-80614
- Archive Date
- 3/30/2010
- Point of Contact
- Thaddeus E Rollins, Phone: 770-488-2427, Vallerie M Redd, Phone: 770-488-2845
- E-Mail Address
-
tnr6@cdc.gov, gfj3@cdc.gov
(tnr6@cdc.gov, gfj3@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- Title of Project: The Electronic Transmission of Molecular Genetics Data to Improve the Completeness and Accuracy of Myeloproliferative Neoplasm (MPN) Reporting to State Cancer Registries. Introduction: "This is a Research and Development (R & D) Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential R & D requirement." The proposed NAICS code for this requirement is 622110. Background. The quality of data collected and reported by central cancer registries depends, in part, upon the completeness of data reporting. Cancer registries are not currently equipped to validate or confirm diagnoses, and thus rely upon the medical practitioner to accurately identify reportable cases. Hematologic cancers are a complex category with pre-cancerous conditions that may transform into malignant forms over a period of time. Their diagnosis is complex and is not pathologically based which adds to the difficulty both in classifying the case by the physician and in capturing the case by the central cancer registries. In a recent investigation of a cluster of polycythemia vera (PV) in Pennsylvania, a new molecular marker (the JAK2 V617F mutation) was used to validate the diagnosis of suspected PV cases. Many of the confirmed PV cases identified by investigators had not been reported to the state cancer registry, and many cases that were reported to the registry did not satisfy the WHO PV diagnostic criteria in existence at the time of diagnosis. These two factors complicated the data analysis and interpretation of results from the cluster investigation and brought into question the reliability of hematologic cancer reporting on a national level. The electronic transmission of JAK2 V617F test results to central cancer registries from clinical laboratories would provide registries with the necessary information to facilitate accurate and complete reporting of PV and other myeloproliferative neoplasms. In addition, the methods developed can be adapted to report molecular markers for other cancers using the same infrastructure. The proposed work is designed to develop and test a system for the electronic reporting of the JAK2 V617F marker that will also serve as a model for other cancer biomarkers. The findings, methods and technology used to implement this project shall be compatible with software currently in use by state cancer registries (eMARC-plus, etc.), will be considered non-proprietary, and will be made available free of charge to laboratories, cancer registries, and other interested parties. Purpose and Objectives. To (1) improve the reporting of PV and other MPNs to state cancer registries by developing a system to electronically transmit JAK2 V617F test results from clinical laboratories to central cancer registries, (2) design and conduct a state laboratory survey to identify gaps in the reporting of MPN and resources required to implement electronic reporting, and (3) disseminate the results of the project to hematologists/oncologists and cancer registries on a national level. Project requirements. 1. Develop methods and specifications for the development or enhancement of software for use by clinical laboratories to electronically report JAK2 V617F test results to central cancer registries. The software will implement filtering of JAK2 V617F tests and transmit the cases to the central cancer registries using an existing national electronic reporting standard. The software must be compatible and interoperable with existing software used by state cancer registries (such as eMaRC Plus, etc.). The software will be tested and evaluated in at least two different laboratories, a hospital or institutional tumor registry, and a state cancer registry. 2. Devise and test a protocol whereby cancer registrars, at the local and/or state levels, pursue case ascertainment derived from electronically reported JAK2 test results. The protocol will include (a) the use of the JAK2 results to confirm previously reported MPN cases, and follow-up for cases with no reported JAK2 testing, (b) follow-up of JAK2 test results for cases not reported to the registry, (c) a mechanism to ensure that all reportable MPN cases identified are submitted to the state cancer registry per regulations, and (d) a final analysis of the volume and completeness of MPN cases reported to the state cancer registry by the participating institutional registries and/or laboratories over the project period compared to data obtained during a past reference period, and the "yield" for reportable MPN cases derived from positive and negative JAK2 test results. 3. Survey a representative sample of clinical laboratories in at least one state to determine the involvement of these labs in molecular genetic testing, including JAK2; the software used to record molecular genetic testing results; and the barriers that must be overcome in order to implement electronic reporting. 4. Disseminate the results, including methods, technologies, and lessons learned from the project to hematologists and cancer registries on a national level. Anticipated period of performance. The period of performance shall be 24 months from the contract award date. Capability statement /information sought. Please explain, in detail, your experience, knowledge and ability to provide the following: Your opinion about the difficulty and or feasibility of the potential requirement or proposed acquisition, possible solutions and approaches that may currently exist in the marketplace, and information regarding innovative ideas or concepts. Your staff expertise, including your availability, experience, and formal and other training. Your current in house capability and capacity to perform the work. Your completed projects of similar nature. Your corporate experience and management capability. Provide any examples of prior completed Government contracts, reference, and other related information. Provide a rough order of magnitude of the effort or time that may be required for completion of the work. The Government will not return capability statements received Information Submission Instructions: Please include a cover page with the following business information: a) DUNS: b) Organization name and address c) Do you have a Government approved accounting system? If so, please identify the agency that approved the system. d) Business size and type of business, (e. g., small business, 8(a), woman owned, veteran owned, etc.) pursuant to the applicable NAICS code 622110, size standards which is $34.5 M. e) Point of Contact, phone, fax and email address of individuals who can verify the demonstrated capabilities identified in the response. Page Limitation: Capability Statements shall be limited to 6 single-spaced pages including cover page. Pages shall be formatted as follows: MS Word, 8 ½ x 11, 12 pitch, Times New Roman font with one (1) inch margins. Response Due Date: Submit capability statements via email to Thaddeus Rollins, Contract Specialist at tnr6@cdc.gov. Should you have any questions concerning this sources sought, please direct your questions directly to the Contracting Officer, Ms. Vallerie Redd at gfj3@cdc.gov. Responses must be submitted not later than 2:30 pm, Eastern Standard Time (EST) by15 March 2010. Capability statements will NOT be accepted after the due date. The Government will not return capability statements received. "Disclaimer and Important Notes. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/HHS-CDC-SS-2010-80614/listing.html)
- Place of Performance
- Address: Contractor's Facility, United States
- Record
- SN02077742-W 20100228/100226235432-a716dccb668c5d642464f2e83d880e26 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |